NTRA - Liquid Biopsy: A Pathway To Earlier And Less Invasive Cancer Detection

• Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test.
• Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient is symptomatic, and most likely in a later stage of cancer.
• Largely as a result, cancer accounts for 609,000 deaths a year in the United States, making it the second leading cause of death.3 Liquid biopsies, however, provide hope.
• This approach can be particularly beneficial for detecting cancers that currently do not have proven screening methods and thus require invasive tissue biopsies.

For further details see: